The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Antiviral Therapy Improves Postoperative Survival in Patients With Hepatocellular Carcinoma: A Randomized Controlled Trial
Abstract
OBJECTIVE: A randomized controlled trial was conducted to find out whether antiviral therapy in patients with hepatitis B-related hepatocellular carcinoma (HCC) improves long-term survival after hepatic resection. BACKGROUND: Despite advances in surgery and in multidisciplinary treatment, there is still no effective adjuvant treatment to prevent HCC recurrence after R0 resection for HCC. Whether antiviral therapy is useful in reducing postoperative HCC recurrence is unclear. METHODS: Between May 2007 and April 2008, patients who received R0 hepatic resection for HBV-related HCC were randomly assigned to receive no treatment (the control group, n = 100) or antiviral therapy (adefovir 10 mg/d, the antiviral group, n = 100). RESULTS: The baseline clinical, laboratory, and tumor characteristics of the 2 groups were comparable. The 1-, 3-, and 5-year recurrence-free survival rates for the antiviral group and the control group were 85.0%, 50.3%, 46.1% and 84.0%, 37.9%, 27.1%, respectively. The corresponding overall survival rates for the 2 groups were 96.0%, 77.6%, 63.1% and 94.0%, 67.4%, 41.5%, respectively. The recurrence-free survival and overall survival for the antiviral group were significantly better than the control group (P = 0.026, P = 0.001). After adjusting for the confounding prognostic factors in a Cox model, the relative risks of recurrence and death for antiviral treatment were 0.651 [95% confidence interval (CI): 0.451-0.938; P = 0.021] and 0.420 (95% CI: 0.271-0.651; P < 0.001). Antiviral therapy was an independent protective factor of late tumor recurrence (HR = 0.348, 95% CI: 0.177-0.687; P = 0.002) but not of early tumor recurrence [hazard ratio (HR) = 0.949, 95% CI: 0.617-1.459; P = 0.810]. CONCLUSIONS: In patients with hepatitis B-related HCC, adefovir antiviral therapy reduced late HCC recurrence and significantly improved overall survival after R0 hepatic resection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Cited by
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., et al. (2020) · Liver Cancer · doi:10.1159/000509424 · Cited by 800
Self-citationRisk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.016 · Cited by 659
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)
Zhou, J., Sun, H.-C., Wang, Z., Cong, W.-M., Wang, J.-H., Zeng, M.-S., Yang, J.-M., Bie, P., Liu, L.-X., Wen, T.-F., et al. (2018) · Liver Cancer · doi:10.1159/000488035 · Cited by 649
Self-citationXie, D.-Y., Ren, Z.-G., Zhou, J., Fan, J., & Gao, Q. (2020) · Hepatobiliary Surgery and Nutrition · doi:10.21037/hbsn-20-480 · Cited by 479
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., Kuang, M., et al. (2023) · Liver Cancer · doi:10.1159/000530495 · Cited by 477
Self-citation
Metadata
- Authors
- Huang, G., Lau, W. Y., Wang, Z.-G., Pan, Z.-Y., Yuan, S.-X., Shen, F., Zhou, W.-P., & Wu, M.-C.
- Venue
- Annals of Surgery
- Published
- 2015-01
- Volume
- 261
- Issue
- 1
- Pages
- 56-66
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2018332308
- Cited by
- 227
- References
- 2
- FWCI
- 9.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiviral Therapy Improves Postoperative Survival in Patients With Hepatocellular Carcinoma: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1097/sla.0000000000000858
- The paper
- Huang, G., Lau, W. Y., Wang, Z.-G., Pan, Z.-Y., Yuan, S.-X., Shen, F., Zhou, W.-P., & Wu, M.-C. (2015). Antiviral Therapy Improves Postoperative Survival in Patients With Hepatocellular Carcinoma: A Randomized Controlled Trial. Annals of Surgery. https://doi.org/10.1097/sla.0000000000000858
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.